Intraventricular Hemorrhage (IVH) in Preterm Infants?Posthemorrhagic Hydrocephalus (PHH) in Preterm Infants
Conditions
Interventions
High-Threshold Group:Lumbar Puncture with Cerebrospinal Fluid (CSF) Drainage?Ommaya Reservoir Placement?Ventriculoperitoneal (VP) Shunt Placement
Low-Threshold Group:Lumbar Puncture with Cerebrospinal Fluid (CSF) Drainage?Ommaya Reservoir Placement?Ventriculoperitoneal (VP) Shunt Placement
Sponsors
The Second Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Study 1 Inclusion Criteria: Infants born at a gestational age of 23-0 to 36-6 weeks, appropriate for gestational age (AGA), with normal neurological development. 2.Study 3 Inclusion Criteria :1.Gestational age ranging from 23+0 to 36+6 weeks Posthemorrhagic hydrocephalus confirmed by cranial ultrasound or other neuroimaging modalities ; 2. No prior history of cerebrospinal fluid diversion interventions before enrollment;3.Before enrollment, the participant has not undergone any cerebrospinal fluid drainage procedures.
Exclusion criteria
Exclusion criteria: 1.Study 1 Exclusion Criteria : 1.Prenatal or postnatal cranial ultrasound abnormalities, including ventriculomegaly, intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), or cerebral malformations ; 2.Complex congenital heart disease, chromosomal abnormalities, inborn errors of metabolism, perinatal asphyxia, or central nervous system infections ; 3. Birth weight or head circumference below the 10th percentile, or head circumference above the 90th percentile for gestational age. 2.Study 3 Exclusion Criteria : 1.Secondary IVH caused by underlying pathologies (including but not limited to congenital malformations, vitamin K1 deficiency, or coagulopathies); 2.Hydrocephalus attributable to alternative etiologies (including but not limited to infections, congenital anomalies, or intracranial mass lesions); 3.Receipt of therapeutic interventions prior to PHH diagnosis or suspicion of active CNS infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Death or occurrence of neurodevelopmental disorders; | — |
Secondary
| Measure | Time frame |
|---|---|
| Whether there is a neurological infection before VP shunt surgery;Whether to perform a V-P shunt surgery for treatment; | — |
Countries
China
Contacts
Public ContactZhenlang Lin
The Second Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed